The first product discovered, p16INK4a (Inhibitor of CDK4/6), is a cyclin dependent kinase (CDK) inhibitor that enforces RB1 tumor suppressive activity by specifically inhibiting CDK4 and CDK6 [108]. This evidence concerns the gene CDKN2A and neoplasm.